# Intramolecular, Visible Light-Mediated Aza Paternò-Büchi Reactions of Unactivated Alkenes

Dominique E. Blackmun, Stephen A. Chamness, and Corinna S. Schindler.

University of Michigan, Department of Chemistry, Willard-Henry-Dow Laboratory, 930 N University Ave., Ann Arbor, MI 48109

Supporting Information Placeholder

ABSTRACT: Azetidines are of particular interest in medicinal chemistry for their favorable properties, including increased resistance to oxidative metabolism and lower lipophilicity. The recent development of [2+2] reactions has significantly benefitted the previously limited methods for azetidine synthesis, but access to more complex architectures still requires further development. Herein we report a visible-light enabled intramolecular [2+2] cycloaddition to access tricyclic azetidines with 3D complex structures and high levels of saturation.

Incorporation of highly substituted, three-dimensional scaffolds into target structures is an essential strategy in medicinal chemistry to facilitate the development of future pharmaceuticals.[1] Current discovery efforts are shifting towards the inclusion of more saturated, complex scaffolds to increase the likelihood of identifying promising lead structures..[1] Benefits from higher saturation and higher complexity range from increased solubility to greater specificity, and lower toxicity, desirable qualities for a drug.[2] Azetidines are 4-membered nitrogen-containing heterocycles that recently garnered a lot of attention as medicinally desirable scaffolds in the quest for new lead compounds in drug design and development.[3] Specifically, azetidines exhibit favorable pharmacokinetic properties and biological activities including decreased lipophilicity, high polarity, and rigidity, in addition to facilitating the rapid build-up of molecular complexity.[1, 2, 4-9] Implementation of azetidines as alternatives for 5- and 6-membered nitrogen-containing heterocycles in current potential therapeutic candidates is known to improve their metabolic stability by enhancing their overall structural rigidity, resulting in enhanced resistance to oxidative metabolism.[3-6] Furthermore, these compounds often exhibit lower lipophilicity and higher polarity, which represent additional important contributions to enhance the efficacy of a compound.[5] For example, 5-HT$_{2C}$ agonists, **1** and **2** identified by Pfizer, differ only in the ring size of the N-heterocycle, yet the azetidine results in a more potent compound with an EC$_{50}$ of 12 nM compared to 273 nM (Fig. 1A).[4]

However, despite these desirable characteristics, the incorporation of azetidines in current pharmaceutical lead compounds remains limited. Importantly, less than 1% of all nitrogen-heterocycles included in current FDA-approved pharmaceuticals are functionalized azetidines.[10] This divide is due to a dearth in efficient synthetic methods to access these desirable 4-membered ring nitrogen-containing heterocycles.[11-15] Among the synthetic strategies most often

Figure 1. A. Azetidines as important scaffolds for current drug design and development. **B.** Currently available synthetic strategies to access functionalized azetidines.

A. Beneficial Effects of Azetidine Scaffolds on Pharmacokinetics

EC$_{50}$ (nM) = 273

EC$_{50}$ (nM) = 12

advantages of azetidines:
• rigid scaffold • high polarity • low lipophilicity • increased metabolic stability

B. Select Synthetic Strategies towards Azetidines

3 nucleophilic substitution

4 strain release

5 lactam reduction

6 [2+2]-cycloaddition aza Paternò-Büchi

Figure 2. A. Intramolecular methodology using excited alkenes. **B.** Intermolecular methodology using excited oximes and unactivated alkenes. **C.** Novel intramolecular methodology using excited oximes and unactivated alkenes.

A. Previously: Intramolecular Aza Paternò-Büchi Reactions; Styrene/Diene Activation

B. Previously: Intermolecular Aza Paternò-Büchi Reactions; Activation of the Isoxazoline

C. This Work: Intramolecular Aza Paternò-Büchi Reactions: Isoxazoline Activation


applied are nucleophilic substitutions (**3**),[13, 14] strain release of azabicyclobutanes (**4**),[13-15] and the reduction of lactams (**5**, Fig. 1B).[13, 14] However, all of these approaches require the synthesis of specific precursors and are prone to limitations in scope. Arguably, the most efficient and direct strategy towards functionalized azetidines relies on [2+2]-cycloaddition reactions between imines and alkenes, or an aza Paternò-Büchi reaction (**6**). Select efficient procedures for these aza Paternò-Büchi reactions have recently been developed, relying on visible light-mediated energy transfer (Fig. 2). These methods harness the triplet energy excited states of either alkenes or oximes, generated upon energy transfer from the triplet excited states of suitable photocatalysts.[16-19] Following this approach, intramolecular aza Paternò-Büchi reactions proceed upon accessing the triplet excited states of activated alkenes (**7**) to undergo the desired [2+2]-cycloaddition with pendant oximes in up to 99% yield to form azetidines (**8**) (Fig. 2A).[16] An intermolecular variant of this transformation was subsequently developed that relies on unactivated alkenes **9** and the triplet excited states of cyclic oximes **10** to promote the formation of azetidines **11** in up to 99% yield (Fig. 2B).[17] Herein we report the development of an intramolecular aza Paternò-Büchi reaction of unactivated alkenes by relying on the design principle of oxime excitation to access complex azetidine scaffolds. Specifically, cyclic oximes react with the unactivated alkene moieties in **12** to result in the formation of tricyclic azetidines **13** to access substrates with opposite substitution patterns in comparison to the previous intermolecular approach. Notably, both metal-based and organic photocatalysts are shown to promote the desired transformation in yields up to 87% and 41% respectively.

To identify optimal conditions for intramolecular aza Paternò-Büchi reactions of unactivated alkenes, we evaluated a range of photocatalysts varying in triplet energies upon irradiation of oxime **14** with blue LED lights (Table 1). Specifically, conversion of oxime **14** with catalytic amounts of photocatalysts displaying a high triplet energy around 60 kcal mol[-1] including Ir(dF(Me)ppy)$_2$(dtbbpy)] and Ir1·PF$_6$ resulted in the formation of azetidine **15** in 73% and 78% yield, respectively (entries 1-2, Table 1). Under otherwise identical reaction conditions, conversion of oxime **14** with **Ir2** gave rise to azetidine **15** with increased yields of 90% (entry 3, Table 1). Using a catalyst with a lower triplet energy of 58.6 kcal mol[-1], *fac*-[Ir(Fppy)$_3$, resulted in a decreased yield of 61% for **15** (entry 4, Table 1). Catalysts with triplet energies below 57 kcal mol[-1] including [Ir(dFppy)$_2$(dtbbpy)]PF$_6$, *fac*-[Ir(ppy)$_3$], and *fac*-[Ir(4'-CF$_3$-

Table 1. Evaluation of photocatalysts in intramolecular, visible light-mediated aza Paternò-Büchi reactions.

entry	photocatalyst	E_T (kcal·mol[-1])	λ (nm)	yield (%)
1	[Ir(dF(Me)ppy)$_2$(dtbbpy)]PF$_6$	60.2	427	73
2	Ir1·PF$_6$	60.1	427	78
3	**Ir2**	60.1	427	**90**
4	*fac*-[Ir(Fppy)$_3$]	58.6	427	61
5	[Ir(dFppy)$_2$(dtbbpy)]PF$_6$	56.4	427	29
6	*fac*-[Ir(ppy)$_3$]	55.4	427	3
7	*fac*-[Ir(4'-CF$_3$-ppy)$_3$]	55.2	427	7
8	Thioxanthone	65.5	427	0
9	2-MeOTx	57.8	427	41
10	2CzPN	60.6	427	41
11	4CzIPN	58.3	427	0
12	Thioxanthone[a]	65.5	427	6
13	2-MeOTx[a]	57.8	427	26
14	2CzPN[a]	60.6	427	38
15	4CzPIN[a]	58.3	427	19
16	**Ir2** (0.2 M)	60.1	427	76
17	**Ir2** (0.1 M)	60.1	427	84
18	**Ir2** (0.05 M)	60.1	427	85
19	**Ir2** (0.01 M)	60.1	427	85
20	no catalyst	-	-	0

Ir1
[Ir(dF(CF$_3$)ppy)$_2$(dtbbpy)]

Ir2
fac-[Ir(dFppy)$_3$]

2CzPN

Conditions: 0.1 mmol **22** and photocatalyst are dissolved in acetonitrile (0.1 M) and the solution was sparged for 10 min. The sample was irradiated with blue LED lamps 16 hours. Percent yield was determined by NMR with mesitylene as internal standard. [a]Ran in toluene for increased solubility of some organic catalysts.

ppy)₃] resulted in diminished formation of azetidine **15** in yields of less than 29% (entries 5-6, Table 1). Organic photocatalysts were also considered under similar conditions, varying the triplet energy of the catalyst used. In particular, utilizing thioxanthone with a higher triplet energy than the optimal iridium catalyst, Ir2, no product was observed (entry 8, Table 1).

Using organic catalysts with lower triplet energies than thioxanthone, 2-MeOTx and 2CzPN, gave rise to azetidine **15** in 41% yield for both catalysts (entries 9-10, Table 1). However, conversion of oxime **14** relying on 4CzIPN exhibiting a triplet energy between 2-MeOTx and 2CzPN failed to provide the desired azetidine **15** (entry 12, Table 1). Suspecting that the solubility of the organic photocatalyst may be influencing the yield, the solvent was switched to toluene. Under these modified reaction conditions, thioxanthone produced trace amounts of azetidine **15** in 6% yield (entry 12, Table 1). 2-MeOTx did not perform as well in toluene as it did in acetonitrile, resulting in a decreased yield of 26%, while 2CzPN performed similarly, producing **15** in 38% yield (entries 13-14, Table 1). 4CzIPN in toluene produced an increased yield of 19% (entry 15, Table 1). The optimal organic catalyst conditions were identified as 2-MeOTx or 2CzPN in acetonitrile, which is the first instance of organic catalysts being used in a visible light-mediated [2+2] cycloaddition between alkenes and oximes to access azetidines products by exciting the oxime to its triplet state.

With an optimal photocatalyst identified, we subsequently focused on further improving the reaction conditions, with a particular emphasis on concentration (Table 2). Specifically, at 0.2 M a conversion of 98% was observed, however the desired product **15** was formed in diminished yields of only 76% (entry 16, Table 1). In comparison, decreasing the concentration to 0.1 M resulted in the formation of azetidine **15** with improved yields of 84% while complete consumption of oxime **14** was observed (entry 17, Table 1). Notably,

did not result in an improvement in yield (entries 18-19, Table 1). Notably, without photocatalyst no formation of azetidine **15** was observed when oximes **14** was irradiated with blue LED light (entry 20, Table 1).

Utilizing the optimized conditions, the substrate scope for intramolecular aza Paternò-Büchi reactions of oximes incorporating unactivated alkenes was explored. The optimal reaction conditions identified proved to be compatible with a variety of alkene substitution patterns, chain lengths, and oxime backbone substituents, providing access to azetidines in up to 87% yield. The trisubstituted alkene substrate resulted in the formation of tricyclic azetidine **15** in 87% yield, while disubstituted alkenes (**19, 20,** and **23**) produced yields up to 68% yield. The optimal reaction conditions were found to tolerate terminal alkenes, which was surprising as the postulated reaction mechanism for this intramolecular aza Paternò-Büchi reaction relied on the formation of a primary radical. Employing substrates incorporating terminal alkenes allows access to azetidines with methylene groups adjacent to the nitrogen, which were previously only accessible using ethylene gas following the former intermolecular reaction protocol. Terminal alkene **16** resulted in a yield of 25%, however this was improved by decreasing the concentration of the reaction to 80%. Substitution adjacent to the ester moiety resulted in a higher yield of 69% for the dimethyl substrate **17** although a decrease in yield to 9% was observed for azetidine **18**, bearing a monomethyl substituent. Conversely, the crotyl ester resulted in a 68% yield of azetidine **19** with a 1:1 mixture of diastereomers. Increasing the size of the substituent to a *n*-propyl group did not improve the diastereoselectivity, however did produce **20** in 61% yield. Importantly, azetidines incorporating 6-membered ring-lactones were similarly readily accessible, albeit in slightly diminished yields compared to their 5-membered ring analogs. The substrate utilizing a terminal alkene resulted in **21** being formed in 6% while the trisubstituted alkene resulted in **22** being formed in an in-

Table 2. Evaluation of the scope of intramolecular, visible light-mediated aza Paternò-Büchi reactions.

15 (87%)   16 (25%, 80%ᵃ)   17 (69%)   18 (9%)   19 (68%; 1:1 d.r.)   20 (61%; 1.1 d.r.)   21 (6%, 25%ᵃ)

22 (41%, 71%ᵃ)   23 (27%)   24 (72%)   25 (22%, 61%ᵃ)   26 (80%)   27 (R = Ph; 58%) / 28 (R = OEt; 28%)   29 (57%)

Conditions: 0.25 mmol isoxazoline and Ir2 (1 mol %) are dissolved in acetonitrile (0.1 M) and the solution is sparged for 10 min. The reaction is irradiated with blue LED lamps (427 nm) for 16-20 hours. ᵃReaction run at 0.01 M on 0.05 mmol scale, yield by HNMR.

decreasing the concentration further to 0.05 M or 0.01 M

creased 41% due to the increased substitution. By decreasing the reaction concentration for **21** and **22**, the yields increased to 25% and 71%, respectively. An acrylate was also tolerated under these optimal reaction conditions, resulting in 27% yield of **23**. Different substitution patterns on the oxime backbone were amenable, including the unsubstituted oxime **26** resulting in 80% yield, which is comparable to the 87% yield of **15** obtained from the corresponding dimethyl substituted oxime. Monosubstituted oximes were tolerated, however yields varied based on the substituent. Specifically, the *n*-butyl substituent azetidine **24** was produced in 72% yield, the highest yield for monosubstituted substrates while phenyl (**27**) and ethyl ether (**28**) resulted in 58% and 28% yields, respectively. Bulkier disubstituted oxime substituents, specifically diphenyl **25** and piperidine **29**, resulted in 22% and 57% yield respectively. Dilution of the reaction for **25** to 0.01 M resulted in an improved yield of 61%. Diluting the reaction for select low yielding substrates resulted in the yields improving, importantly, the increasing of the yield for terminal alkene **17**, demonstrates that terminal alkenes can work as well as the trisubstituted alkenes under more dilute conditions.

Herein, we report the development of an intramolecular visible light-enabled [2+2]-cycloaddition reaction between unactivated alkenes and cyclic oximes to access tricyclic azetidines in yields up to 87%. This transformation relies on an iridium photocatalyst but can similarly be promoted by an organic photocatalyst to achieve yields of the desired product of up to 41%, resulting in complex, highly saturated scaffolds. Notably, this method gives rise to a reverse substitution pattern in comparison to previous methods developed,[16,17] allowing access to molecules that occupy distinct chemical space. We anticipate this new strategy to be used for the rapid build-up of molecular complexity when incorporating functionalized azetidines in current drug design and development.

ASSOCIATED CONTENT

Supporting Information. The Supporting Information is available free of charge on the ACS Publications website and includes experimental procedures, characterization (^{1}H-NMR, ^{13}C-NMR, IR, and MS data), additional optimization and control experiments (pdf format).

AUTHOR INFORMATION

Corresponding Author

* Email: corinnas@umich.edu.

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interests.

ACKNOWLEDGMENT

REFERENCES

(1) Lovering, F.; Bikker, J.; Humblet, C., Escape from flatland: increasing saturation as an approach to improving clinical success. *J. Med. Chem.* **2009**, *52*, 6752-6756. https://doi.org/10.1021/jm901241e.

(2) Lovering, F., Escape from Flatland 2: complexity and promiscuity. *Med. Chem. Commun.* **2013**, *4*, 515-519. https://doi.org/10.1039/C2MD20347B.

(3) Bauer, M. R.; Di Fruscia, P.; Lucas, S. C. C.; Michaelides, I. N.; Nelson, J. E.; Storer, R. I.; Whitehurst, B. C., Put a ring on it: application of small aliphatic rings in medicinal chemistry. *RSC Med. Chem.* **2021**, *12*, 448-471. https://doi.org/10.1039/D0MD00370K.

(4) Fish, P. V.; Brown, A. D.; Evrard, E.; Roberts, L. R., 7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 1871-5. https://doi.org/10.1061/j.bmcl.2009.02.071.

(5) St Jean, D. J., Jr.; Fotsch, C., Mitigating heterocycle metabolism in drug discovery. *J. Med. Chem.* **2012**, *55*, 6002-6020. https://doi.org/10.1021/jm300343m.

(6) Shu, Y. Z.; Johnson, B. M.; Yang, T. J., Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery. *AAPS J.* **2008**, *10*, 178-192. https://doi.org/10.1208/s12248-008-9016-9.

(7) Lowe, J. T.; Lee, M. D. t.; Akella, L. B.; Davoine, E.; Donckele, E. J.; Durak, L.; Duvall, J. R.; Gerard, B.; Holson, E. B.; Joliton, A.; Kesavan, S.; Lemercier, B. C.; Liu, H.; Marie, J. C.; Mulrooney, C. A.; Muncipinto, G.; Welzel-O'Shea, M.; Panko, L. M.; Rowley, A.; Suh, B. C.; Thomas, M.; Wagner, F. F.; Wei, J.; Foley, M. A.; Marcaurelle, L. A., Synthesis and profiling of a diverse collection of azetidine-based scaffolds for the development of CNS-focused lead-like libraries. *J. Org. Chem.* **2012**, *77*, 7187-7211. https://doi.org/10.1021/jo300974j.

(8) Brown, A.; Brown, T. B.; Calabrese, A.; Ellis, D.; Puhalo, N.; Ralph, M.; Watson, L., Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 516-520. https://doi.org/10.1016/bmcl.2009.11.097.

(9) Maetani, M.; Zoller, J.; Melillo, B.; Verho, O.; Kato, N.; Pu, J.; Comer, E.; Schreiber, S. L., Synthesis of a Bicyclic Azetidine with In Vivo Antimalarial Activity Enabled by Stereospecific, Directed C(sp(3))-H Arylation. *J. Am. Chem. Soc.* **2017**, *139*, 11300-11306. https://doi.org/10.1021/jacs.7b06994.

(10) Vitaku, E.; Smith, D. T.; Njardarson, J. T., Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. *J. Med. Chem.* **2014**, *57*, 10257-10274. https://doi.org/10.1021/jm501100b.

(11) Cromwell, N. H.; Phillips, B., The Azetidines. Recent Synthetic Developments. *Chem. Rev.* **1979**, *79*, 331-358. https://doi.org/10.1021/cr60320a003.

(12) Richardson, A. D.; Becker, M. R.; Schindler, C. S., Synthesis of azetidines by aza Paterno-Buchi reactions. *Chem. Sci.* **2020**, *11*, 7553-7561. https://doi.org/10.1039/D0SC01017K.

(13) Brandi, A.; Cicchi, S.; Cordero, F. M., Novel syntheses of azetidines and azetidinones. *Chem. Rev.* **2008**, *108*, 3988-4035. https://doi.org/10.1021/cr800325e.

(14) Antermite, D.; Degennaro, L.; Luisi, R., Recent advances in the chemistry of metallated azetidines. *Org. Biomol. Chem.* **2016**, *15*, 34-50. https://doi.org/10.1039/C6Ob01665K.

(15) Gianatassio, R.; Lopchuk, J. M.; Wang, J.; Pan, C. M.; Malins, L. R.; Prieto, L.; Brandt, T. A.; Collins, M. R.; Gallego, G. M.; Sach, N. W.; Spangler, J. E.; Zhu, H.; Zhu, J.; Baran, P. S., Organic chemistry. Strain-release amination. *Science* **2016,** *351*, 241-246. https://doi.org/10.1126/science.aad6252.

(16) Becker, M. R.; Richardson, A. D.; Schindler, C. S., Functionalized azetidines via visible light-enabled aza Paterno-Buchi reactions. *Nat. Commun.* **2019**, *10*, 5095. https://doi.org/10.1038/s41467-019-13072-x.

(17) Becker, M. R.; Wearing, E. R.; Schindler, C. S., Synthesis of azetidines via visible-light-mediated intermolecular [2+2] photocycloadditions. *Nat. Chem.* **2020**, *12*, 898-905. https://doi.org/10.1038/s41557-020-0541-1.

(18) Wearing, E. R.; Blackmun, D.E.; Schindler, C. S., 1- and 2-Azetines via Visible Light-Mediated [2+2]-Cycloadditions of Alkynes and Oximes. *J. Am. Chem. Soc.* **2021**, *143*, 16235-16242. https://doi.org/10.1021/jacs.1c07523.

(19) Rykaczewski, K.A.; Schindler, C. S. Visible-Light-Enabled Paternò-Büchi Reaction via Triplet Energy Transfer for the Synthesis of Oxetanes. *Org. Lett.* **2020**, *22*, 6516-6519. https://doi.org/10.1021/acsorglett.0c02316.